MARKET

IBRX

IBRX

ImmunityBio Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.19
-0.29
-2.53%
Closed 19:01 07/29 EDT
OPEN
11.55
PREV CLOSE
11.48
HIGH
11.72
LOW
11.14
VOLUME
586.54K
TURNOVER
--
52 WEEK HIGH
45.42
52 WEEK LOW
6.03
MARKET CAP
4.30B
P/E (TTM)
-12.3184
1D
5D
1M
3M
1Y
5Y
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that based on results from its 2021 Annual Me...
Business Wire · 15h ago
Soon-Shiong Sees His Shot as a Universal Booster
Bloomberg · 21h ago
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022
CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that ImmunityBio, Inc. (NASDAQ: IBRX) ("Imm...
Business Wire · 23h ago
ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent
CULVER CITY, Calif., July 27, 2021--ImmunityBio, Inc., a publicly traded immunotherapy company, announced today that it has been granted a patent by the U.S. Patent and Trademark Office for its proprietary NANT Cancer Vaccine (U.S. Patent 11,071,774). This...
Business Wire · 2d ago
ImmunityBio Receives US Patent for NANT Cancer Vaccine Treatment
MT Newswires · 3d ago
Billionaire Soon-Shiong Sees His Covid Shot as Universal Booster
Bloomberg · 3d ago
Meridian Investment Counsel Inc. Buys SPDR MSCI ACWI ex-US ETF, ImmunityBio Inc, Travel+Leisure ...
GuruFocus News · 6d ago
Stocks That Hit 52-Week Lows On Monday
  Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
Benzinga · 07/19 14:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBRX. Analyze the recent business situations of ImmunityBio Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IBRX stock price target is 25.00 with a high estimate of 25.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 166
Institutional Holdings: 16.79M
% Owned: 4.37%
Shares Outstanding: 383.91M
TypeInstitutionsShares
Increased
38
4.17M
New
44
1.37M
Decreased
32
714.32K
Sold Out
20
436.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.49%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Executive Director
Patrick Soon-Shiong
President/Chief Executive Officer/Director
Richard Adcock
Chief Financial Officer
David Sachs
Senior Vice President - Finance
Sonja Nelson
Other/Director
Barry Simon
Independent Director
Michael Blaszyk
Independent Director
John Brennan
Independent Director
Wesley Clark
Independent Director
Cheryl Cohen
Independent Director
Linda Maxwell
Independent Director
Christobel Selecky
No Data
About IBRX
Immunitybio, Inc., formerly NantKwest, Inc., is a late-clinical-stage immunotherapy company developing therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The Company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T-cell) immune systems to create long-term immunological memory. The Company is engaged in developing molecular and product platforms based on three key modalities: activating NK and T cells using antibody cytokine fusion proteins, activating tumoricidal macrophages using low-dose synthetic immunomodulators, and generating memory T cells using vaccine candidates developed with second-generation adenovirus (hAd5) technology. It is also developing therapies, including vaccines, for the prevention and treatment of human immunodeficiency virus (HIV), influenza, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its human adenovirus (hAd5) vaccine technologies.

Webull offers kinds of Immunitybio Inc stock information, including NASDAQ:IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.